Irving, Stephanie A.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 435

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 398

Risk of anaphylaxis after vaccination in children and adults.

McNeil, M. M., Weintraub, E. S., Duffy, J., Sukumaran, L., Jacobsen, S. J., Klein, N. P., Hambidge, S. J., Lee, G. M., Jackson, L. A., Irving, S. A., et al. (2016) · Journal of Allergy and Clinical Immunology

Food Allergy and Anaphylaxis ResearchPharmacovigilance and Adverse Drug Reactions

Cited by 381

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · BMJ

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 185

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Link-Gelles, R., Levy, M. E., Gaglani, M., Irving, S. A., Stockwell, M., Dascomb, K., DeSilva, M. B., Reese, S. E., Liao, I.-C., Ong, T. C., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 126

Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15.

Donahue, J. G., Kieke, B. A., King, J. P., Mascola, M. A., Shimabukuro, T. T., DeStefano, F., Hanson, K. E., McClure, D. L., Olaiya, O., Glanz, J. M., et al. (2019) · Vaccine

Influenza Virus Research StudiesPharmacovigilance and Adverse Drug Reactions

Cited by 59

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

Link-Gelles, R., Levy, M. E., Natarajan, K., Reese, S. E., Naleway, A. L., Grannis, S. J., Klein, N. P., DeSilva, M. B., Ong, T. C., Gaglani, M., et al. (2022) · medRxiv

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 10